We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
ASX up as mining gains offset tech and bank losses Silex, Paladin and uranium stocks soar on supply...
Read ArticleASX up, Xero leads gains Miners hit as iron ore drops, Variscan jumps 50pc Asian stocks down, Bitco...
Read ArticleASX slipped after early gains, then finished strongly Energy sector helped offset losses; Quickste...
Read ArticleASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results...
Read ArticleHealthcare stocks are doing relatively well globally in 2024 The sector could see more recovery as...
Read ArticleASX slips as US jobs data fuels Wall Street panic Westpac gets a new CEO Newcomers into the ASX...
Read ArticleLumos Diagnostics to raise $10 million, with a little help from an iron-ore baron Memphasys is not...
Read ArticleASX likely to fall sharply after Nvidia’s 9.5pc drop Alphabet, Microsoft, and Apple all also took m...
Read ArticleASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing;...
Read ArticleS&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expec...
Read ArticleS&P/ASX 200 had its best month of the year in July finishing up 4% to record high S&P Dow J...
Read ArticleASX rises on Thursday Nine sectors end higher, led by property stocks Small caps led by BEZ T...
Read ArticleThe EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-l...
Read ArticleASX rises on Monday after Wall Street banked a belter on Friday All 11 local sectors higher, InfoT...
Read ArticleNeuren’s NNZ-2591 receives a Rare Pediatric Disease Designation from US FDA This could lead to a Pr...
Read ArticleNeuren’s NNZ-2591 receives a Rare Pediatric Disease Designation from US FDA This could lead to a Pr...
Read ArticleGood morning, and welcome to Stockhead’s Top 10 at shortly-after-11-ish, which is meant to highlight...
Read ArticleThe ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biot...
Read ArticleASX rises +0.5pc driven by tech, banking, and property sectors This comes as US Fed maintains rates...
Read ArticleS&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biot...
Read ArticleResearch shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase th...
Read ArticleASX 200’s rally was driven mainly by gold/silver and iron ore stocks Gold prices hit record high as...
Read ArticleASX flat on Monday, ahead of Federal Budget Tuesday night Oil weakness drags Energy sector lower C...
Read ArticleCash here is becoming like the orange-bellied parrot – highly endangered – despite the folding stuff...
Read ArticleASX Health sector was in correction territory in April Why is the health sector different from othe...
Read ArticleThere’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to c...
Read ArticleBy Tim Boreham, Editor ASX code: ((HYD)) Market cap: $4.3m Shares on issue: 254,218,847 Financials (...
Read ArticleThe ASX200 has ended RBA Day comfortably higher Materials lead gains as iron ore prices rise Small...
Read ArticleWith the RBA’s interest rates decision due tomorrow, the ASX200’s expected to open marginally higher...
Read ArticleASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essenti...
Read ArticleViking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on p...
Read ArticleASX200 dragged down by bad drugs The IT Sector is up 1.1pc, Healthcare is down about 3.2pc Small...
Read ArticleXi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for t...
Read ArticleASX200 closes 0.9pc higher Property stocks and IT sector enjoy huge day Small caps led by DCL Th...
Read ArticleGood morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, to highlight the best (and...
Read ArticleAustralian biotechnology company, Memphasys says a $1.3 million research and development tax refund...
Read ArticleAustralian biotechnology company, Memphasys says a $1.3 million research and development tax refund...
Read ArticleBenchmark ASX index closes at new 12-month lows Energy and Materials the worst of 9 dipping ASX sec...
Read ArticleNews relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD f...
Read ArticleL’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supr...
Read ArticleJust when all looked lost for a group of parent hopefuls in India, a piece of Australian medical tec...
Read ArticleJust when all looked lost for a group of parent hopefuls in India, a piece of Australian medical tec...
Read ArticleASX200 is making a strong run into the weekend – up 1.5 per cent with all sectors ahead. Seismic...
Read ArticleMemphasys’s (MEM) FELIX sperm separation technology has led to 11 successful pregnancies and births...
Read ArticleMemphasys reported 10 new live births in India using its Felix system Ramsay Health Care’s credit r...
Read ArticleThe FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergenc...
Read ArticleStockhead’s Top 10 at shortly-before-11-ish, published shortly after I’ve located my reading glasses...
Read ArticleEarnings reports dominated headlines in August Despite solid results from ASX healthcare giants, th...
Read ArticleAustralian biotech has attracted US investments in the last five years Among ASX stocks to get fund...
Read ArticleBiotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two g...
Read ArticleThe ASX 200 benchmark has climbed down from highs at lunch to finish on +0.39%. Health Care was we...
Read ArticleASX benchmark falls 0.86% for the day, dragged down by bad news from China. Telcos, Energy and Inf...
Read ArticleJust a week into its pivotal deal with global IVF provider Vitrolife, reproductive biotechnology com...
Read ArticleFirebrick achieved primary endpoint in Phase 2 Memphasys rise 20pc after distribution deal in Japan...
Read ArticleStockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) pe...
Read ArticleThe ASX will open lower on Monday Wall Street megacaps mainly fell on Friday This week’s focus will...
Read ArticleReproductive technology specialist Memphasys has inked an exclusive five-year distribution deal with...
Read ArticleThe end of pandemic and higher rates have subdued biotech market But there are signs now the sector...
Read ArticleReproductive biotechnology company Memphasys been granted two new Australian patents for its flagshi...
Read ArticleBrisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “gam...
Read ArticleSmall cap health stocks are not known to pay dividends But there’s a handful of such stocks on the...
Read ArticleBiotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We...
Read ArticleThe ASX fell this morning and – sadly – just never recovered. It’s down 0.64%. Aside from Happy Tim...
Read ArticleS&P/ASX 200 closes up 0.6%, while the emerging companies index rises 0.86% Austral’s US subsidi...
Read ArticleArtificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discove...
Read ArticleDespite the materials sector having a tough run today on the back of lower gold, silver and copper p...
Read ArticleMemphasys (MEM) reports the first live birth of a healthy baby boy in India using its Felix system a...
Read ArticleAussie shares to extend gains on Monday after a rally in New York EU inflation continues to be at r...
Read ArticleThe ASX is expected to open the new week higher ahead of the much-anticipated RBA rates decision on...
Read ArticleWhat’s wrong with our tadpoles, gentlemen? According to local fertility expert Prof John Aitken, spe...
Read ArticleThe ASX extended the week’s losses by falling 0.4% today Star Entertainment Group posted a loss so...
Read ArticleShareCafeThe Week that Was: February 6-10, 2023 We at ShareCafe understand you are busy and may not...
Read ArticleShareCafeMemphasys (ASX: MEM) Felix System Findings Memphasys (ASX: MEM) has announced the first pu...
Read ArticleShareCafeASX closes 0.46% lower after RBAs 25 basis point hike by Peter Milios The Reserve Bank of...
Read ArticleThis content is created by Smallcaps Authors. [Author : Imelda Cotton] In vitro results from study...
Read ArticleCreso looks to potentially spin out psychedelic subsidiary Two studies show Memphasys’ Felix repr...
Read ArticleShareCafeASX up 0.12% at noon as investors await this afternoon’s RBA meeting by Peter Milios Inve...
Read ArticleShareCafeStocks of the Hour: C29, EVR, MEM C29 Metals (ASX:C29) advises tha...
Read Article07 Feb 2023 - A snapshot of the stocks on the move featuring C29 Metals (ASX:C29), EV Resources (ASX...
Read ArticleThe FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have g...
Read ArticleJapanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based devic...
Read ArticleThe ASX 200 rose a tidy 1.29% today with all sectors in the green ABS releases Aussie migrant data...
Read ArticleThe ASX 200 was in the red again, down 0.21% today 9 out 11 sectors finished lower led by Real Esta...
Read ArticleASX health stocks have been out of favour this year with rotation away from growth to value sector...
Read ArticleWall St surged after a media report signalled the Fed might be slowing down its rate hikes from Dec...
Read ArticleWe take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks fr...
Read ArticleBlood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks...
Read ArticleSmall cap index up 1.1%, stronger than benchmark, but both do good, run hard. Wall Street snaps 3...
Read ArticleSmall caps and benchmark down over 1% All sectors retreat on ill-winds blowing in from the states T...
Read ArticleStockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) per...
Read ArticleSmall caps creep up 0.018%, ASX 200 stays flat Energy sector jumps with Karoon Energy and Terracom...
Read ArticleThe ASX200 is down 0.24% dragged down by the tech sector Eight out of eleven sectors were lower, wi...
Read ArticleThe ASX200 is up 0.31% with the ABS reporting strong wage growth Seven out of eleven sectors were h...
Read ArticleReproduction biotechnology and bio-separations company Memphasys (MEM) launches a $3.36 million cap...
Read ArticleASX 200 is up 0.2% and the XEC is down -0.2% Tension stateside ahead of FOMC decision, EU markets t...
Read ArticleReproduction biotechnology and bio-separations company Memphasys (MEM) enters a mid-week trading ha...
Read ArticleWhile the bigger end of the towns tides out pre-earnings blackouts, small caps are making the most o...
Read ArticleUS FDA approves the first clinical trial using naturally derived psychedelic drugs It could open po...
Read ArticleA recent research reveals which biotech segments VCs are ploughing billions of dollars into We list...
Read ArticleSydney biotechnology company Memphasys has passed another milestone on the route to commercialising...
Read ArticleMemphasys (MEM) has enrolled and treated the first couple under a clinical study trialling the safe...
Read ArticleAvita Medical makes spray on skin for burns and soft tissue injuries HITIQ’s concussion tech is pop...
Read ArticleAustralian reproductive biotechnology company Memphasys is taking advantage of the worldwide easing...
Read ArticleNeurotech says its cannabis strain NTI164 demonstrates strong results when combined with Diclofenac...
Read ArticleStockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) per...
Read ArticleEmerging markets index ends flat ASX200 0.5 higher Chinese economy hit by COVID-lockdowns Anaemi...
Read ArticleEmerging markets index ends flat ASX200 0.5 higher Chinese economy hit by COVID-lockdowns Anaemi...
Read ArticleThe Healthcare sector has been struggling as the pandemic wanes But most money managers are still b...
Read ArticleThe healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak mark...
Read ArticleIt’s been an emotional ride for fans of the ASX200 (XJO) which, alongside the Emerging Companies (XE...
Read ArticleBiotech sector has had a tough time recently But there are signs of things improving this year A lo...
Read ArticleThe ASX 200 index has closed 1% higher on Monday, while the ASX Emerging Companies (XEC) index shed...
Read ArticleTrailblazing biotech Memphasys has achieved a crucial step in the rollout of its IVF sperm separatio...
Read ArticleTelehealth was already a growing space even before the pandemic, but COVID had launched it into the...
Read ArticleStockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) per...
Read ArticleThe ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial t...
Read ArticleThe price action of ASX biotech shares was nothing short of a mixed bag in 2021. Several of the ma...
Read ArticleAt the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, be...
Read ArticleIt’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and...
Read ArticleThe life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, th...
Read ArticleMemphasys has landed the first sale of its revolutionary trademarked Felix bio-separation technology...
Read ArticleMemphasys is rapidly hurtling towards commercialising with its “Felix” IVF reproductive technology....
Read ArticleInvesting in ASX biotech shares was an underwhelming affair in November. As a basket, the sector la...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 los...
Read ArticleEach week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength In...
Read ArticleFor the second month in a row the ASX was hit by a major sell-off in the last few days of the month...
Read ArticleMemphasys has successfully collected data from approximately 240 horse inseminations to test its nov...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 los...
Read ArticleThe Australian bourse recouped most of yesterday’s losses despite tech stocks dropping again, this t...
Read ArticleReproduction biotechnology and bio-separations company Memphasys (MEM) completes the maiden sale of...
Read ArticleThe ASX 200 Health Index (XHJ) is down by 0.35% at the time of writing, compared to the broader inde...
Read ArticleThe hot debut of Evolution Energy Minerals (ASX:EV1) was not enough to save the ASX resources sector...
Read ArticleThe benchmark S&P/ASX 200 index (ASX: XJO) has slipped 0.75% into the red today at 7,414 points...
Read ArticleLocal stocks posted a solid session on Wednesday ahead of this week’s main event on global markets l...
Read ArticleAlthough earnings results were the main theme in August, there were also some notable healthcare bre...
Read ArticleLocal stocks struggled for traction in Wednesday trade, as the major indexes drifted sideways follow...
Read ArticleWall Street inches lower overnight All three US stock market indexes finished slightly lower overnig...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 7...
Read ArticleShareCafeMemphasys Taking on One of Humanity’s Most Pressing Issues Humanity has a profound demograp...
Read ArticleThe ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the...
Read ArticleUnlisted company Ellume is making headlines again with reports claiming Australian governments are...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 7...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has ret...
Read ArticleClosing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading d...
Read ArticleThe Full 180 is a fortnightly look at ASX capital raisings. We are entering our fourth week (or so)...
Read ArticleClosing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at th...
Read ArticleLarge and small caps had diverging fates on the ASX today with the former closing 0.32 per cent down...
Read ArticleThe ASX notched up gains today despite one of the biggest IPOs this year dropping on debut. The ASX...
Read ArticleSummary The ASX 200 opened higher by 0.10% on Tuesday after the US stocks closed on a strong not...
Read ArticleMedtech company Oneview Health (ASX:ONE) led 25 stocks that chalked up a 14-day RSI above 70 this we...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks f...
Read ArticleSource: S_L ,Shutterstock Summary Memphasys Limited revealed that the validation process of its...
Read ArticleSperm sorter Memphasys (ASX:MEM) is down 40 per cent after a major setback. The company’s Felix devi...
Read ArticleEllume, a small Brisbane-based private biotech company, is in the news today. And for good reason –...
Read ArticleThe companies have been recognised for design and engineering excellence at the Good Design Awards.
Read ArticleA quick wrap of the ASX’s key winners and losers on Monday, July 27. Data is taken after the market...
Read ArticleShareCafeWhat Have Been The Best “Hidden Gems” Webinar Performers? Over the past three months, Share...
Read ArticleA quick wrap of the ASX’s key winners and losers on Friday, July 10. Data is taken after the market...
Read ArticleShareCafeMemphasys Ltd – ShareCafe Hidden Gems Webinar Presentation Memphasys Ltd CEO and Executi...
Read ArticleShareCafeHidden Gems Webinar Recap – SPT, KZA, MEM, ANP We continue to unearth small-cap companie...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small ca...
Read ArticleA quick wrap of the key winners and losers on Friday, May 1. Data is taken after the market closes a...
Read ArticleThe announcement lands just before markets open, ‘the TGA has approved our device’; the buy orders b...
Read ArticleShareCafeMemphasys – The Business Of IVF Treatments Memphasys – The Business Of IVF TreatmentsCompa...
Read ArticleStockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and pickin...
Read ArticleAnother ASX small cap has won the blessing of the Food and Drug Administration (FDA) for its product...
Read ArticleYou don’t need a PhD to run a biotech, but sometimes it helps, as these companies deal in one of the...
Read ArticleDid the doc say to take one pill twice daily, or two tablets once daily? When it comes to correct me...
Read ArticleDid you know that a hard-working stallion ejaculates 100 times more sperm than the average bloke? Gi...
Read ArticleThis year has been a positive one for ASX small caps. According to Bloomberg, the average small cap...
Read ArticleAustralian Health Care is a dynamic sector with a potential to generate significant profits in the l...
Read ArticleOn Stockhead today: the three biggest opportunities for digital transformation in pharma, why it’s t...
Read Article
Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
